In the September issue of Pharmaceutical Executive, Lev Gerlovin addresses four main questions that US drugmakers must answer to cope with the evolving payer landscape given rising drug prices. To read the article, click the link below.
12 CRA consultants named top IP professionals in the 2021 IAM Patent 1000
12 CRA consultants were recognized as leading patent professionals by Intellectual Asset Management (IAM). The IAM Patent 1000 names the best-in-class patent...